The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20 ...
A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle ...
A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an ...
Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...
A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle ...
Edgewise Therapeutics, Inc., (NASDAQ:EWTX) revealed topline results from the Phase 2 CANYON trial of sevasemten in ...
Wood, PhD, President and CEO, Muscular Dystrophy Association. “I am proud to see the impact that our Muscular Dystrophy Association advocates made in urging USDOT to take decisive action. We will ...
There are, however, data to support various medical and device-based approaches to management of cardio myopathy, and the cardiomyopathy associated with muscular dystrophy should not be an exception.
Diagnosed at age 11 with muscular dystrophy, Vergara prioritizes giving back to his communities. A new laptop would help him do that.
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results